The effect of oral L-arginine supplementation on asymmetric dimethylarginine levels: A systematic review and meta-analysis of randomized clinical trials

Nichols, 2014, Cardiovascular disease in Europe 2014: epidemiological update, Eur. Heart J., 35, 2950, 10.1093/eurheartj/ehu299 Kearney, 2004, Worldwide prevalence of hypertension: a systematic review, J. Hypertens., 22, 11, 10.1097/00004872-200401000-00003 Oparil, 2003, Pathogenesis of hypertension, Ann. Intern. Med., 139, 761, 10.7326/0003-4819-139-9-200311040-00011 Forman, 2009, Diet and lifestyle risk factors associated with incident hypertension in women, Jama, 302, 401, 10.1001/jama.2009.1060 Geleijnse, 2004, Impact of dietary and lifestyle factors on the prevalence of hypertension in Western populations, Eur. J. Publ. Health, 14, 235, 10.1093/eurpub/14.3.235 Endemann, 2004, Endothelial dysfunction, J. Am. Soc. Nephrol., 15, 1983, 10.1097/01.ASN.0000132474.50966.DA Tran, 2003, The ddah/adma/nos pathway, Atheroscler. Suppl., 4, 33, 10.1016/S1567-5688(03)00032-1 Sydow, 2003, ADMA and oxidative stress, Atheroscler. Suppl., 4, 41, 10.1016/S1567-5688(03)00033-3 Moncada, 1993, The L-arginine-nitric oxide pathway, N. Engl. J. Med., 329, 2002, 10.1056/NEJM199312303292706 Borghi, 2017, Nutraceuticals with a clinically detectable blood pressure-lowering effect: a review of available randomized clinical trials and their meta-analyses, Br. J. Clin. Pharmacol., 83, 163, 10.1111/bcp.12902 Böger, 2004, Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor, J. Nutr., 134, 2842S, 10.1093/jn/134.10.2842S Jabecka, 2012, Oral L-arginine supplementation in patients with mild arterial hypertension and its effect on plasma level of asymmetric dimethylarginine, L-citruline, L-arginine and antioxidant status, Eur. Rev. Med. Pharmacol. Sci., 16, 1665 Schneider, 2015, Effects of chronic oral L-arginine administration on the L-arginine/NO pathway in patients with peripheral arterial occlusive disease or coronary artery disease: L-arginine prevents renal loss of nitrite, the major NO reservoir, Amino Acids, 47, 1961, 10.1007/s00726-015-2031-0 Walker, 2001, Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance, J. Am. Coll. Cardiol., 38, 499, 10.1016/S0735-1097(01)01380-8 Lucotti, 2009, Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass, Metabolism, 58, 1270, 10.1016/j.metabol.2009.03.029 Sydow, 2003, ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst (e) inemia: effects of L-arginine and B vitamins, Cardiovasc. Res., 57, 244, 10.1016/S0008-6363(02)00617-X Bode-Böger, 2003, Oral L-arginine improves endothelial function in healthy individuals older than 70 years, Vasc. Med., 8, 77, 10.1191/1358863x03vm474oa Jadad, 1996, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Control. Clin. Trials, 17, 1, 10.1016/0197-2456(95)00134-4 Higgins, 2002, Quantifying heterogeneity in a meta‐analysis, Stat. Med., 21, 1539, 10.1002/sim.1186 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, Bmj, 315, 629, 10.1136/bmj.315.7109.629 Lentz, 2003, Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA, Atheroscler. Suppl., 4, 61, 10.1016/S1567-5688(03)00035-7 Smith, 2003, Dimethylarginine dimethylaminohydrolase activity modulates ADMA levels, VEGF expression, and cell phenotype, Biochem. Biophys. Res. Commun., 308, 984, 10.1016/S0006-291X(03)01507-9 Anderssohn, 2010, Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus, Diab. Vasc. Dis. Res., 7, 105, 10.1177/1479164110366053 Mangoni, 2009, The emerging role of symmetric dimethylarginine in vascular disease, Adv. Clin. Chem., 48, 73, 10.1016/S0065-2423(09)48003-X Antoniades, 2011, Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis, Hypertension, 58, 93, 10.1161/HYPERTENSIONAHA.110.168245 Böger, 1998, Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction, Circulation, 98, 1842, 10.1161/01.CIR.98.18.1842 Altun, 2008, Effects of oral L-arginine supplementation on blood pressure and asymmetric dimethylarginine in stress-induced preeclamptic rats, Cell Biochem. Funct., 26, 648, 10.1002/cbf.1491 Lin, 2002, Impaired nitric oxide synthase pathway in diabetes mellitus, Circulation, 106, 987, 10.1161/01.CIR.0000027109.14149.67 Böger, 2007, Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: effect of combination with oral L-arginine, J. Am. Coll. Cardiol., 49, 2274, 10.1016/j.jacc.2007.02.051 Deveaux, 2016, A slow-compared with a fast-release form of oral arginine increases its utilization for nitric oxide synthesis in overweight adults with cardiometabolic risk factors in a randomized controlled study, J. Nutr., 146, 1322, 10.3945/jn.116.231910 Monti, 2015, Pharmacogenetic influence of eNOS gene variant on endothelial and glucose metabolism responses to L-arginine supplementation: post hoc analysis of the L-arginine trial, Metabolism, 64, 1582, 10.1016/j.metabol.2015.08.015 Rytlewski, 2005, Effects of prolonged oral supplementation with L‐arginine on blood pressure and nitric oxide synthesis in preeclampsia, Eur. J. Clin. Invest., 35, 32, 10.1111/j.1365-2362.2005.01445.x Cross, 2001, Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure, Kidney Int., 60, 2318, 10.1046/j.1523-1755.2001.00059.x Alvares, 2012, Acute L-arginine supplementation does not increase nitric oxide production in healthy subjects, Nutr. Metab., 9, 54, 10.1186/1743-7075-9-54 Böger, 1998, Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease, J. Am. Coll. Cardiol., 32, 1336, 10.1016/S0735-1097(98)00375-1 Willoughby, 2011, Effects of 7 days of arginine-alpha-ketoglutarate supplementation on blood flow, plasma L-arginine, nitric oxide metabolites, and asymmetric dimethyl arginine after resistance exercise, Int. J. Sport Nutr. Exerc. Metab., 21, 291, 10.1123/ijsnem.21.4.291